Biodesix continues growth in test volume and reaffirms 2026 revenue outlook
BDSX Biodesix Inc
$9.79 -3.26%
View chart & analysis → - 1Biodesix test volume growth rates rose from 23% to 29% to 38% for three consecutive quarters.
- 2The Street expects Biodesix to report a loss per share of $0.74 and revenue of $27.3 million.
- 3Management reaffirmed the 2026 revenue range of $108 million to $114 million.
So what's the key point?
Biodesix test volumes have increased significantly for three consecutive quarters. Experts expect the company's revenue to reach $27.3 million.
Source Earnings Whispers · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.